In our study, we showed that BC with high LAG-3+CK+ cell numbers had worse treatment outcomes with PD-L1/PD-1 inhibitor, whereas BC with high LAG-3+CK- cell numbers had better outcomes compared to those with both low LAG-3+CK+ and low LAG-3+CK- cells. The gene discussed is CD274; the disease is breast cancer.